JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coleman, C. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Coleman, C. I.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Coronary disease
Right arrow Electrophysiology - arrhythmias

J Thorac Cardiovasc Surg 2008;136:1101
© 2008 The American Association for Thoracic Surgery

Letter to the Editor

Reply to the Editor:

Craig Ian Coleman, PharmD

University of Connecticut School of Pharmacy, Storrs, Conn

The first 20% of the full text of this article appears below.

My coauthors and I thank Drs Kourliouros, Roberts, and Jahangiri for their interest in our recent study.1Go We do not disagree with their suggestion that different statins may exhibit varying degrees of pleiotropic effects (eg, anti-inflammatory effects), and thus believe that their hypothesis that statins may have differential abilities to prevent postcardiothoracic surgery (CTS) atrial fibrillation is not unreasonable. It is, however, important to note that the intent . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.